Mostra i principali dati dell'item
dc.contributor.author | García Sanz, Ramón | |
dc.contributor.author | Montoto, Silvia | |
dc.contributor.author | Torrequebrada, Agustín | |
dc.contributor.author | García de Coca, Alfonso | |
dc.contributor.author | Petit, José | |
dc.contributor.author | Sureda, Anna | |
dc.contributor.author | García Rodríguez, José Antonio | |
dc.contributor.author | Massó, Pilar | |
dc.contributor.author | Pérez Aliaga, Ana | |
dc.contributor.author | Monteagudo, María Dolores | |
dc.contributor.author | Navarro, Isabel | |
dc.contributor.author | Moreno, Gemma | |
dc.contributor.author | Toledo, Carmen | |
dc.contributor.author | Alonso, Aránzazu | |
dc.contributor.author | Besses, Carles | |
dc.contributor.author | Besalduch, Joan | |
dc.contributor.author | Jarque, Isidro | |
dc.contributor.author | Salama, Perla | |
dc.contributor.author | Hernández Rivas, José Ángel | |
dc.contributor.author | García Navarro, Blanca | |
dc.contributor.author | Bladé, Joan | |
dc.contributor.author | San Miguel Izquierdo, Jesús Fernando | |
dc.date.accessioned | 2024-02-05T10:50:23Z | |
dc.date.available | 2024-02-05T10:50:23Z | |
dc.date.issued | 2001-12 | |
dc.identifier.citation | García‐Sanz, R., Montoto, S., Torrequebrada, A., De Coca, A. G., Petit, J., Sureda, A., ... & Miguel, J. F. S. (2001). Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. British journal of haematology, 115(3), 575-582. https://doi.org/10.1046/j.1365-2141.2001.03144.x | es_ES |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | http://hdl.handle.net/10366/155313 | |
dc.description | Fue un trabajo descriptivo extenso que dio origen al grupo español Macroglobulinemia de Waldenström, que desde entonces y hasta hoy está liderado por el Dr. García Sanz y es uno de los principales grupos internacionales en esta patología, con contribuciones relevantes en el campo clínico, pronósti-co y biológico | es_ES |
dc.description.abstract | [EN]In this report we analyse the presenting features of a series of patients diagnosed with Waldenström macroglobulinaemia (WM) in Spain over the last 10 years. Criteria for diagnosis required a serum monoclonal IgM protein > or = 30 g/l and > 20% bone marrow lymphocytes. Two hundred and seventeen patients were included in the study, with a median age of 69 years and male/female ratio of 2:1. The most common symptoms at diagnosis were anaemia (38%), hyperviscosity (31%), B symptoms (23%), bleeding (23%) and neurological symptoms (22%). Sixty-one patients (27%) were asymptomatic at diagnosis and, to date, 32 of them have not received chemotherapy. Variables predicting a shorter survival free of therapy were haemoglobin < 12.5 g/dl and high beta2microglobulin (beta2M). The 83% of patients who did receive treatment were distributed as follows: chlorambucil/prednisone (43%), intermittent chlorambucil (11%), continuous chlorambucil (26%), cyclophosphamide/vincristine/prednisone (COP, 13.5%) and other (6.5%). Response to therapy was complete in 2%, partial in 48% and minor in 10%. Finally, 28% and 13% of patients presented stable and progressive disease, respectively, which was more common among patients treated with COP. Progression-free survival was 43% at 5 years, with three independent predictors for shorter progression-free survival (PFS): COP treatment, age > 65 and B symptoms at diagnosis. The 10-year projected overall survival (OS) was 55%. The two most frequent causes of death were development of second malignancies (31%), or infections (19%). The two main variables predicting a poor OS were hyperviscosity and high beta2M. In summary, this study favours the use of chlorambucil-based therapy as the standard treatment for WM, and describes a subset of patients who should be considered as suffering a smouldering form and who therefore do not require treatment for a long period of time. | es_ES |
dc.description.sponsorship | University Hospital of Salamanca Universidad de Salamanca | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | CC0 1.0 Universal | * |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.subject | Myeloma | es_ES |
dc.subject | Waldenstrom Macroglobulinemia | es_ES |
dc.subject | Immunoglobulin M | es_ES |
dc.subject | Prognosis | es_ES |
dc.subject.mesh | beta 2-Microglobulin | * |
dc.subject.mesh | Aged | * |
dc.subject.mesh | Chlorambucil | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Antineoplastic Agents | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Lymphocytes | * |
dc.subject.mesh | Waldenstrom Macroglobulinemia | * |
dc.subject.mesh | Prognosis | * |
dc.subject.mesh | Immunoglobulin M | * |
dc.subject.mesh | Antibodies | * |
dc.subject.mesh | Treatment Outcome | * |
dc.subject.mesh | Survival Rate | * |
dc.subject.mesh | Lymphocyte Count | * |
dc.subject.mesh | Incidence | * |
dc.title | Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publishversion | https://doi.org/10.1046/j.1365-2141.2001.03144.x | es_ES |
dc.subject.unesco | 3205.04 Hematología | es_ES |
dc.identifier.doi | 10.1046/j.1365-2141.2001.03144.x | |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.pmid | 11736938 | |
dc.identifier.essn | 1365-2141 | |
dc.journal.title | British Journal of Haematology | es_ES |
dc.volume.number | 115 | es_ES |
dc.issue.number | 3 | es_ES |
dc.page.initial | 575 | es_ES |
dc.page.final | 582 | es_ES |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
dc.subject.decs | inmunoglobulina M | * |
dc.subject.decs | humanos | * |
dc.subject.decs | anciano | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | recuento de linfocitos | * |
dc.subject.decs | linfocitos | * |
dc.subject.decs | tasa de supervivencia | * |
dc.subject.decs | incidencia | * |
dc.subject.decs | pronóstico | * |
dc.subject.decs | microglobulina-beta 2 | * |
dc.subject.decs | clorambucilo | * |
dc.subject.decs | resultado del tratamiento | * |
dc.subject.decs | macroglobulinemia de Waldenström | * |
dc.subject.decs | antineoplásicos | * |
dc.subject.decs | anticuerpos | * |
dc.description.project | Hospital Universitario de Salamanca | es_ES |
dc.description.project | Hospital Universitario de Salamanca | es_ES |